Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ris-Rez · 4 trials · 4 indications
OS is defined as the time from the date of randomization to the date of death by any cause
cORR is defined as the proportion of participants who have confirmed Complete Response (CR) or Partial Response (PR), assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1
Number of participants will be assessed
Number of participants will be assessed
Number of participants will be assessed
Number of participants will be assessed
Number of participants will be assessed
Number of participants will be assessed
PFS is defined as the time from the date of randomization until the date of documented disease progression or death due to any cause, whichever occurs first, as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)
Confirmed ORR is defined as the proportion of participants who have achieved a confirmed Complete Response (CR) or Partial Response PR as assessed by investigator, according to RECIST 1.1
cORR is defined as the proportion of participants who have confirmed Complete response (CR) or Partial response (PR), assessed by the investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST V1.1) criteria or other imaging criteria for defined tumor types.
| Arm | Type | Description |
|---|---|---|
| Ris-Rez | EXPERIMENTAL | - |
| Topotecan | ACTIVE_COMPARATOR | - |
| Ris-Rez + Ivonescimab | EXPERIMENTAL | - |
| Cohort 1A (Ris-Rez) | EXPERIMENTAL | - |
| Cohort 1B [Ris-Rez + Granulocyte-Colony Stimulating Factor (G-CSF)] | EXPERIMENTAL | - |
| Cohort 2 (Ris-Rez) | EXPERIMENTAL | - |
| Phase 1a- Dose escalation- Monotherapy | EXPERIMENTAL | - |
| Phase 1a- Dose escalation- Combination therapy | EXPERIMENTAL | - |
| Phase 1b- Dose optimisation- Monotherapy | EXPERIMENTAL | - |
| Phase 1b- Dose optimisation- Combination therapy | EXPERIMENTAL | - |
| Phase 1b- Dose expansion- Monotherapy | EXPERIMENTAL | - |
| Phase 1b- Dose expansion- Combination therapy | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Ris-Rez | BIOLOGICAL | Ris-Rez will be administered |
| Topotecan | DRUG | Topotecan will be administered |
| Ivonescimab | BIOLOGICAL | Ivonescimab will be administered |
| G-CSF | BIOLOGICAL | G-CSF will be administered |
| Cisplatin | DRUG | Cisplatin will be administered |
| Carboplatin | DRUG | Carboplatin will be administered |
| Atezolizumab | BIOLOGICAL | Atezolizumab will be administered |
| Pembrolizumab | BIOLOGICAL | Pembrolizumab will be administered |
| Durvalumab | BIOLOGICAL | Durvalumab will be administered |
| Cetuximab | BIOLOGICAL | Cetuximab will be administered |
| Bevacizumab | BIOLOGICAL | Bevacizumab will be administered |
| Tarlatamab | BIOLOGICAL | Tarlatamab will be administered |
| Dostarlimab | BIOLOGICAL | Dostarlimab will be administered |
Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply: * Adults \>18 or the minimum legal adult age at the time the informed consent form is signed * Has histologically or cytologically confirmed extensive-stage small cell lung cancer...
Ris-Rez is an investigational monoclonal antibody being developed for oncology indications, including solid tumors, sarcoma, and lung cancer. It is currently in clinical development for advanced solid tumors, relapsed small cell lung cancer, advanced sarcomas, and in combination with ivonescimab for advanced solid tumors.
Ris-Rez is being developed by GSK plc, a global biopharma company traded on the London Stock Exchange under the ticker GSK. GSK is conducting multiple clinical trials of Ris-Rez across various oncology indications.
Ris-Rez is in Phase 1 clinical development for most indications, including advanced solid tumors and sarcomas. However, one trial in relapsed small cell lung cancer is listed as Phase 3. The drug is investigational and not yet approved by regulatory authorities.
Ris-Rez is being studied in four clinical trials: NCT06551142 for advanced solid tumors, NCT07099898 for relapsed small cell lung cancer, NCT07602777 for advanced sarcomas, and NCT07602855 in combination with ivonescimab for advanced solid tumors. All trials are recruiting or not yet recruiting.
Yes, Ris-Rez is also known as GSK5764227 and Risvutatug Rezetecan. Clinical trial NCT06551142 uses the name GSK5764227, while trials NCT07602777 and NCT07602855 use the name Risvutatug Rezetecan.